2 unknown. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Unknown 1 |
Follow Tian Xie: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study Elemene plus first or third generation EGFR-TKIs, First or third generation EGFR-TKIs - Carcinoma, Non-Small-Cell Lung Cancer | Phase 4 | Unknown | Tian Xie | 744 | 2020-11-09 | 2023-12-27 |
| Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study Carcinoma, Non-Small-Cell Lung | Unknown | Tian Xie | 878 | 2020-08-28 | 2023-12-27 |
Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma (1) · Carcinoma (1)
aflutinib (1) · aumolertinib (1) · elemene (1)
China (2)
Ziping Wang, PhD (2)